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ABSTRACT: The BRCA1 tumor suppressor gene is found
mutated in familial breast cancer. Although many of the
mutations are clearly pathological because they give rise
to truncated proteins, several missense variants of
uncertain pathological consequences have been identi-
fied. A novel functional assay to screen for BRCA1
missense variants in a simple genetic system could be
very useful for the identification of potentially deleterious
mutations. By using two prediction computer programs,
Sorting Intolerant from Tolerant (SIFT) and Polymorph-
ism Phenotyping (PolyPhen), seven nonsynonymous
missense BRCA1 variants likely disrupting the gene
function were selected as potentially deleterious. The
budding yeast Saccharomyces cerevisiae (S. cerevisiae) was
used to test these cancer-related missense mutations for
their ability to affect cell growth and homologous
recombination (HR) at the HIS3 and ADE2 loci. The
variants localized in the BRCA1 C-Terminus (BRCT)
domain did not show any growth inhibition when
overexpressed in agreement with previous results. Over-
expression of either wild-type BRCA1 or two neutral
missense variants did not increase yeast HR but when
cancer-related variants were overexpressed a significant
increase in recombination was observed. Results clearly
showed that this genetic system can be useful to
discriminate between neutral and deleterious BRCA1
missense variants.
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Introduction
In the Western world, one of the most common neoplasia of
women is breast cancer, which affects approximately 6 out of 100
women before the age of 74 years. About 80% of breast cancers is
sporadic and is diagnosed in women without any familial
aggregation. However, the remaining 20% of cases are inheritable
and about 40% of those are caused by mutations in one of the two
tumor suppressor genes, BRCA1 (MIM] 113705) and BRCA2
(MIM] 600185) [Miki et al., 1994; Wooster et al., 1994].
The tumor suppressor BRCA1 gene encodes a nuclear
phosphoprotein that is involved in many cellular processes
including homologous recombination (HR) and DNA repair
[Narod and Foulkes, 2004]. The gene is highly polymorphic, with
many common single-base changes. Many of the germ-line
mutations found in BRCA1 give rise to truncated nonfunctional
proteins that can predispose to breast and ovarian cancer.
However, the pathological consequence of many missense muta-
tions found in breast and/or ovarian cancer families remains to be
ascertained.
Several predictive methods have been proposed to distinguish
cancer-related variants from neutral polymorphisms, including
the pattern of cosegregation of the variant with disease in
affected carrier families [Goldgar et al., 2004], the nature and the
position of amino acid substitution [Grantham, 1974; Mirkovic
et al., 2004], the degree of conservation among species [Abkevich
et al., 2004], and the inactivation of the wild-type allele either
by loss of heterozygosity (LOH) or promoter hypermethylation
in the tumor of the carrier[Blackwood and Weber, 1998].
Recently, a combined method that integrates the molecular
biology data with the familial and clinical history has been useful
classify the missense mutations [Osorio et al., 2007]. Several
functional assays to identify missense mutations of BRCA1 are
also available [Carvalho et al., 2007]; some methods take
advantage of the ability of the BRCT domain to activate the
transcription of a reporter gene both in mammalian cells and in
Saccharomyces cerevisiae (S. cerevisiae) [Phelan et al., 2005].
Other functional assays rely on the ability of BRCA1 mutations
to rescue the radiation resistance of the BRCA1 defective
HCC1937 human cell line or are based on the determination of
the ubiquitin ligase activity, mediated by the interaction of the
RING domain of BRCA1 with the BARD1 gene [Carvalho et al.,
2007; Scully et al., 1999].
The expression of human wild-type BRCA1 in the budding
yeast S. cerevisiae inhibits growth and this peculiar phenotype has
been exploited to characterize several missense mutations [Coyne
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et al., 2004; Humphrey et al., 1997]. A functional assay named
‘‘yeast small colony phenotype assay’’ (SCP) has been proposed to
evaluate the pathogenicity of BRCA1 missense mutations. In
general, the SCP assay can only identify mutations localized within
the BRCT and this is in agreement with predictions based on
structure modeling [Coyne et al., 2004].
In this study, we identified several BRCA1 missense variants
by the mutational analysis of 276 breast and/or ovarian
cancer families. By in silico analysis, seven missense variants
were identified as potentially not functional. Then, we tested
them for the identification of potentially deleterious mutations
by SCP assay. Moreover, as BRCA1 is involved in HR and the
yeast is an excellent genetic model system to investigate
factors affecting HR, we determined the effect of BRCA1
missense variant expression on yeast HR at two distinct
chromosomal loci (HIS3 for intrachromosomal and ADE2 for
interchromosomal recombination). Results clearly indicate that
the yeast S. cerevisiae can be a very helpful tool to classify BRCA1
missense variants.
Materials and Methods
Samples
DNA samples from 276 individuals belonging to 276 breast
and/or ovarian cancer families were analyzed for BRCA1 and
BRCA2 germline mutations. All patients were from the University
Hospital of Pisa. The selection criteria were as follows: 1)
occurrence of two or more cases of breast and/or ovarian cancer
in first or second-degree relatives; 2) early onset of the disease
(o50 years of age); 3) occurrence of bilateral breast cancer; or 4)
occurrence of breast and ovarian cancer in the same individual.
Mutation Screening
The screening of mutations in the BRCA1 and BRCA2 genes
was performed by direct sequencing. DNA sequencing was carried
out using BigDye terminator v 3.1 mix (Applera-Applied
Biosystems, Foster City, CA) and different primers (available
upon request). Capillary gel electrophoresis and data collection
was performed on an automated DNA sequencer (ABI 3100;
Applera-Applied Biosystems). Sequences analysis were performed
using SeqScape Software (Applera-Applied Biosystems).
Variant Selection
To identify nonsynonymous amino acid changes likely to
disrupt BRCA1 gene function we used two comparative
evolutionary bioinformatic programs: Sorting Intolerant From
Tolerant (SIFT; http://blocks.fhcrc.org/sift/SIFT.html) and Poly-
morphism Phenotyping (PolyPhen; http://tux.embl-heidelberg.de/
ramensky/polyphen.cgi).
SIFT is a multiple sequence alignment tool based on the
premise that important amino acids will be conserved among
species in a protein family, so that changes of amino acids
conserved in the family should affect protein function [Ng and
Henikoff, 2003]. PolyPhen is an automatic tool for prediction of
possible impact of an amino acid substitution on the structure and
function of a human protein [Ramensky et al., 2002].
The DNAmutation numbering is based on the cDNA sequence of
BRCA1 (GenBank: U14680.1), with a ‘‘c’’ symbol before the
number. For the numbering, 11 corresponds to the A of the ATG
translation initiation codon in the reference sequence, following the
journal guidelines (www.hgvs.org/mutnomen). Otherwise, the DNA
mutation nomenclature is as in the Breast Cancer Information Core
(BIC) database according to reference sequence GenBank U14680.1,
where 11 corresponds to the first base of exon 1.
LOH Analysis
LOH analysis was carried out on tumor tissue excised from the
index individual case of each family. Neoplastic and normal cells
were collected separately by manual microdissection from 7-mm
sections of the formalin-fixed paraffin-embedded breast carcino-
ma tissue block. The DNA was extracted from the dissected tumor
and normal cells using a QIAamp DNA Mini Kit (Qiagen, Hilden,
Germany). Amplification was carried out by PCR using primers
located in the exon in which the missense variant was identified
and the resulting products were analyzed by sequencing on an ABI
PRISM 3100 Genetic Analyzer (Applied Biosystems). Sequences
analysis were performed using SeqScape Software. If one of the
two bases identified in the electropherogram at the same position,
corresponding to the variant position, disappeared, the sample
was scored as positive for LOH.
BRCA1 Promoter Methylation Profile
DNA was extracted from formalin-fixed paraffin-embedded
tumoral sections after manual microdissection. The methylation
profile of BRCA1 gene promoter was evaluated by methylation
specific PCR (MSP) using the EZ DNA methylation kit
(Zymo Research, Orange, CA). The method is based on the
conversion of unmethylated cytosines to uracil by sodium bisulfite
treatment. By using specific primers that distinguish methylated
cytosines from unmethylated cytosines uracil-transformed in
the same promoter region, it is possible to PCR amplify
differentially methylated DNA. We considered a promoter as
methylated if a PCR product is obtained by using primers specific
for methyl-CpG.
Plasmids and DNA Manipulation
The plasmid YCpGAL::BRCA1 which contains the human
BRCA1 gene under the galactose-inducible promoter GAL1p was
obtained from Craig Bennett (Duke University, Durham, NC)
[Westmoreland et al., 2003]. The missense variants were constructed
by site-directed mutagenesis with specific oligonucleotides using
QuikChange II XL site-directed mutagenesis kit (Stratagene, La Jolla,
CA). The primer sequence is available upon request.
Plasmid DNA preparation was carried out using the Wizard
miniprep kit (Promega, Madison, WI). The mutations were
checked by DNA sequence analysis.
Yeast Strain
The diploid strain RS112 of S. cerevisiae, obtained from Robert
Schiestl (University of California, Los Angeles [UCLA], Los
Angeles, CA) has the following genotype: MATa/MATa ura3-52/
ura3-52 leu2-3,112/leu2-D98 trp5-27/TRP5 ade2-40/ade 2-101 ilv1-
92/ilv1-92 arg4-3/ARG4 his3D50-pRS6-his3D30/his3-D200 LYS2/
lys2-801. Media preparation and yeast culturing was carried out
according to standard techniques. Yeast was transformed with
plasmid DNA by using the lithium acetate method with single-
strand DNA as carrier, following the procedure described in [Gietz
et al., 1995]. Transformants were selected in solid medium lacking
uracil (SC–URA). Colonies were grown for 4 days at 301C and
analyzed further.
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Protein Extract Preparation and Western Blotting
The level of BRCA1 expression was determined in yeast cells
transformed with the BRCA1 expression vector after 24 hr
induction in galactose medium. Single clones were pregrown in
10–20ml of SC–URA glucose medium for 24 hr at 301C. Then, cell
pellets were washed in water and split in two aliquots: one was
inoculated in 20ml of SC–URA glucose and the other one in 20ml
of SC–URA galactose. The cultures were incubated at 301C for
24 hr under constant shaking. Thereafter, pellets were washed
twice in ice cold water and resuspended in 0.5ml of suspension
buffer (50mM KCl, 5mM MgCl2, 0.1M EDTA, 25mM HEPES,
5mM dithiothreitol, 0.3M (NH4)2SO4, and 10% glycerol; pH 7.4)
plus 10ml of protease inhibitor solution (4.4mg phenylmethylsul-
phonyl fluoride, 62mg pepstatin, 50mg chemostatin, and 725ml
DMSO in 1ml H2O). Total protein extracts were prepared
according to the method of Kimmerly et al. [1988]. Cell lysis was
performed by vortexing five times for 30 s with acid-washed glass
beads [Del Carratore et al., 2004]. A total of 30 mg of protein yeast
extract was electrophoresed on a 6% SDS-polyacrylamide gel and
transferred overnight in a cold room on a polyvinylidene fluoride
membrane. BRCA1p is analyzed using anti-BRCA1 monoclonal
antibody Ab4 diluted 1:100 (clone SD118; Calbiochem, Gibbs-
town, NJ), which recognizes the exon 11 of the BRCA1 protein.
Anti-mouse horseradish peroxidase-linked (Amersham Bios-
ciences, Piscataway, NJ), diluted 1:5,000, is used as secondary
antibody. As loading control, we determined the level of the 3-
phosphoglycerate kinase (PGK) with the anti-&agr3PGK antibody
from Molecular Probes (Invitrogen, Carlsbad, CA).
SCP Assay
For each missense variants three independent transformants
were analyzed. Single colonies were picked up from –URA glucose
plates and inoculated in 5ml liquid –URA medium containing 2%
glucose. Under these growth conditions the synthesis of BRCA1 is
repressed. Cultures were then incubated at 301C for 48 hr under
constant shaking. Thereafter, cells were counted, diluted in sterile
distilled water, and plated in SC–URA plates containing 5%
galactose. Usually, 200–250 cells per dish were plated. Under these
conditions, the GAL1 promoter confers a high level of protein
expression [Galli and Schiestl, 1998]. Plates were incubated at
301C for 4–6 days or until colonies reached the largest size. Then,
three colonies were picked up from each plate, resuspended in
1ml sterile water, and counted with a hemocytometer.
Intra- and Interchromosomal Recombination Assay
The RS112 strain was constructed from the haploid RSY6 and,
consequently, carries the same intrachromosomal recombination
substrate as RSY6 [Schiestl et al., 1988, 1989]. This substrate
consists of two his3 alleles, one with a deletion at the 30 end and
the other with a deletion at the 50 end, which share 400 bp of
homology. These two alleles are separated by the LEU2 marker
and by the plasmid DNA sequence. An intrachromosomal
recombination event leads to HIS3 reversion and loss of LEU2
[Schiestl et al., 1988]. The diploid RS112 strain also contains the
two alleles ade2-40 and ade2-101, located in two homologous
chromosomes that allow the measurement of interchromosomal
recombination events [Schiestl, 1989]. To determine the frequency
of intrachromosomal and interchromosomal recombination,
single colonies were inoculated into 5ml of SC–URA–LEU
medium and incubated at 301 C for 24 hr. Thereafter, cultures
were washed twice in sterile distilled water and counted. For each
BRCA1 variant as well as the BRCA1wt and the controls, aliquots
containing 107 cells were inoculated in 5ml of SC–URA–LEU
medium containing 5% galactose. In parallel, the same number of
cells was inoculated in 5ml of SC–URA–LEU glucose-containing
medium. Both glucose and galactose cultures were incubated at
301C for 24–30 hr under constant shaking. Thereafter, cells were
washed twice, counted, and appropriate numbers were plated onto
complete medium to determine the number of vital cells, and onto
solid medium lacking histidine or adenine to determine the
frequency of intrachromosomal and interchromosomal recombi-
nation, respectively. The RS112 strain carrying the empty vector
was exposed to methyl methanesulfonate (MMS) as follows:
aliquots containing 5 107 cells/ml were inoculated in a total
volume of 5ml (107 cells/ml) of SC–URA–LEU glucose or
galactose with different doses of MMS. Then, cultures were
incubated at 301C for 4 hr under shaking, washed, counted, and
plated as described [Schiestl, 1989; Schiestl et al., 1989].
Data Comparison and Statistical Analysis
The frequency of recombination obtained after growth in galactose
medium was compared to that in glucose medium. For each BRCA1
protein, at least six independent experiments were carried out.
Results were statistically analyzed using the Student’s t-test.
Results
SIFT and PolyPhen Prediction Programs Identify Probably
Deleterious Nonsynonymous Missense Variants
The mutational analysis of 276 hereditary breast and ovarian
cancer families, performed by automatic direct sequencing of all
coding regions and intron–exon boundaries, has revealed several
novel as well as previously described variants of BRCA1 gene. By
using two prediction software programs, SIFT and PolyPhen, seven
nonsynonymous variants likely disrupting the gene function,
p.N132K, p.Y179C, p.N550H, p.S1164I, p.S1512I, p.I1766S,
p.A1789T, were identified. Among those, two variants, the
3610G4T (c.3491G4T, p.S1164I) and the 5484G4A
(c.5365G4A, p.A1789T), were studied for the first time in this
analysis; the variant 5416T4G (c.5295T4G, p.I1766S) has been
classified as deleterious mutation by other studies [Carvalho et al.,
2007]. Three have been previously reported as probably neutral: the
655A4G (c.536A4G, p.Y179C) has been reported by Judkins et al.
[2005]; the 1767A4C (c.1648A4C, p.N550H) was classified as
probably neutral by Tavtigian et al. [2006]; and the 515C4A
(c.396C4A, p.N132K) has been reported as likely to be of no or
little clinical significance by Easton et al. [2007]. Finally, the variant
4654G4T (c.4535G4T, p.S1512I) was reported as neutral by
Deffenbaugh et al. [2002] and confirmed by Tavtigian et al. [2006].
Out of the 13, 6 were predicted as neutral by both programs:
477G4A (c.358G4A, p.D120N); 1118A4G (c.999A4G,
p.T333A); 1575T4C (c.1575T4C, p.F486L); 2576T4C
(c.2457T4C, p.S819P); 3147C4T (c.3028C4T, p.P1010S); and
5057G4A (c.4956G4A, p.M1652I). Two of them, p.F486L and
p.P1010S, were selected as negative controls; p.F486L was previously
reported as neutral variant [Judkins et al., 2005], whereas p.P1010S
has never been reported before. Summary information on the 13
BRCA1 missense variants is reported in Table 1.
Finally, three known missense variants (p.C61G, p.A1708E, and
p.M1775R) previously reported as deleterious mutations were
chosen as positive (i.e., loss of function) controls; the first one
maps in the RING FINGER domain and the last two in the BRCT
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domains [Ruffner et al., 2001; Carvalho et al., 2007]. The
mutation p.C61G is due to a G to T transversion at nt 181 of
the BRCA1 cDNA. p.A1708E is due to a C4A transversion at nt
5123 of the BRCA1 cDNA, and p.M1775R it is due to a T4G
transversion at nt 5324 of the BRCA1 cDNA. The location of
selected missense variants and negative and positive controls is
depicted in Figure 1.
Each selected variant was found in a single family with the
exception of the three variants, p.Y179C, p.F486L, and p.N550H,
which were found to be associated in two unrelated families.
The control variants p.C61G, p.A1708E, and p.M1775R were
not found in the breast and ovarian cancer family group we
studied. The histopathological features of the proband’s tumor are
shown in Table 2.
Segregation Analysis
Familial history information was available for all carriers of the
variants considered and the pedigrees are included in the
Supplementary Figs. S1 and S2 (available online at http://
www.interscience.wiley.com/jpages/1059-7794/suppmat). The seg-
regation analysis of the variant allele with the disease was performed
only in Families PI403, PI397, PI258, and PI222, for which DNA
samples of unaffected or affected relatives were available.
The variants p.Y179C and p.N550H were both detected in two
unrelated families, Families PI403 and PI340, in which the neutral
variant p.F486L has also been found. The proband from Family
PI403 was affected by breast cancer at 42 years of age. Two second-
degree relatives in the paternal branch, the proband’s grandmother
and a cousin, were affected by breast cancer. The affected cousin was
found negative for the variants (Supplementary Figs. S1 and S2).
The variant p.S1164I was detected in Family PI397, also the
carrier of the p.E1172X BRCA1 deleterious mutation. The
proband was unaffected, but her mother and three of her
mother’s sisters were affected by ovarian cancer; moreover, four
third-degree relatives were affected by breast and ovarian cancer.
We showed the presence of a variant allele, in association with the
deleterious mutation, in a unaffected cousin and an unaffected
aunt of the proband, and their absence in three unaffected cousins
of the proband (Supplementary Fig. S1).
The variant p.A1789 T was detected in Family PI258. The
proband was affected by breast cancer at 32 years of age. The
proband’s mother, affected by breast and ovarian cancer diagnosed
at 46 and 50 years of age, respectively, was found to be the carrier
of the variant (Supplementary Fig. S1).
The variant p.I1766S was found in Family PI222. The proband
had ovarian carcinoma diagnosed at 42 years of age. A DNA
sample was available from an unaffected sister of the proband; she
tested negative for the mutation (Supplementary Fig. S1).
Inactivation of the BRCA1wt Allele by LOH or Promoter
Methylation
The inactivation of the wild-type allele in the tumor tissue of
the patient carrying the variant allele is considered to be indicative
of the pathogenicity of such a variant. Inactivation may occur
through loss of part of a chromosome, detected by LOH analysis,
or by gene expression silencing due to promoter hypermethyla-
tion. LOH analysis of four cases and a methylation profile of two
cases was performed.
LOH was not observed in the tumor DNA of the p.N132K
carrier in Family PI432.
The wild-type allele was lost in the tumor DNA of the proband
of Family PI340 carrying the three variants p.Y179C, p.F486L, and
p.N550H.
The tumor DNA of both patients carrying the variant p.A1789 T
showed no LOH of the wild-type allele but the methylation
profile of BRCA1 gene promoter of both samples showed
hypermethylation.
Co-Occurrence
Co-occurrence is really a test for embryonic lethality due to
inheritance of a compound heterozygous null genotype. The
underlying assumption is that inheritance of a genuine high-risk
missense substitution in BRCA1, along with a clearly deleterious
Table 1. Description of the BRCA1 Missense Variants Analyzed
BRCA1 varianta
Systematic
nomenclatureb
Number of families
harboring the variant Siftc Polyphend BICe Pathogenicity Previous classification
477G4A, p.D120N c.358G4A 1 0.25 0.45 0 Null Not classified
515C4A, p.N132K c.396C4A 1 0 1.924 1 Damaging Neutral [Easton et al., 2007]
655A4G, p.Y179Cf c.536A4G 2 0.03 2.41 35 Damaging Probably neutral [Judkins et al., 2005]
1118A4G, p.T333A c.999A4G 1 0.19 1.151 0 Null Not classified
1575T4C, p.F486Lf c.1456T4C 2 0.71 0.815 37 Null Neutral [Judkins et al., 2005]
1767A4C, p.N550Hf c.1648A4C 2 0.13 1.570 35 Probably
deleterious
Probably neutral [Judkins et al., 2005]
2576T4C, p.S819P c.2457T4C 1 0.08 0.08 0 Null Not classified
3147C4T, p.P1010S c.3028C4T 1 0.9 0.618 0 Null Not classified
3610G4T, p.S1164I c.3491G4T 1 0.01 2.158 0 Damaging Not classified
4654G4T, p.S1512I c.4535G4T 2 0.03 1.77 50 Damaging Neutral [Tavtigian et al., 2006]
5075G4A, p.M1652I c.4956G4A 4 0.00 1.713 39 Probably neutral Neutral Tavtigian et al., 2006]
5416T4G, p.I1766S c.5295T4G 1 0.01 1.94 5 Damaging Deleterious [Carvalho et al., 2007]
5484G4A, p.A1789T c.5365G4A 1 0.02 1.23 0 Probably deleterious Not classified
aDNA mutation nomenclature is as used in the BIC database (http://research.nhgri.nih.gov/bic) according to GenBank accession number U14680.1 with numbering starting at
the first residue.
bMutation nomenclature listed with a ‘‘c.’’ uses GenBank cDNA reference sequence U14860.1 with 11 corresponding to the A of the ATG translation initiation codon in the
reference sequence, following the journal guidelines (www.hgvs.org/mutnomen).
cPo0.05, deleterious substitution.
dScore: 1.5–2, probably damaging substitution; and 42, damaging substitution.
eNumber of times that the variant has been described in Breast Cancer Information Core (http://research.nhgri.nih.gov/bic/) revised in January 2006.
fBoth patients with the p.Y179C variant also carried the p.F486L and the p.N550H variants.
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mutation, will lead to death during embryogenesis. The method has
the pitfall that the clearly deleterious mutation and the sequence
variant of interest must be in trans for the analysis to be valid. We
evaluated the co-occurrence in our sample of 276 families. Only the
variant p.S1164I was found to co-occur in a family (Family PI397)
in which a deleterious mutation was found. This variant co-occurs
with the stop mutation p.E1172X in all six individuals we tested in
the family, so we supposed that it is localized in the same allele (in
cis), with respect to the deleterious mutation.
The BRCT Missense Variants Inhibit the Growth
Suppression Phenotype
The expression of the wild-type BRCA1 gene inhibits growth in
S. cerevisiae [Humphrey et al., 1997]. Taking advantage of this
phenotype, the SCP assay has been proposed to distinguish cancer
predisposing missense mutations from harmless polymorphisms
[Coyne et al., 2004]. In this study, we constructed 12 missense
mutations localized throughout the whole sequence of the BRCA1
gene. To further validate the SCP assay, we constructed one
mutant within the RING FINGER domain, two mutants down-
stream from this domain, four mutants in the DNA binding
domain, one in the serine and threonine (SQ) cluster domain, and
four in the BRCT domains (Fig. 1). The vector allows a high level
of protein expression when galactose is present in the culture
medium [Humphrey et al., 1997]. To determine if the BRCA1 was
expressed in the RS112 strain, we carried out Western blot analysis
of the total protein extract from yeast culture in galactose. The
BRCA1wt protein was expressed after 24 hr in galactose (Fig. 2A,
lane 1). No protein was seen when the same culture was grown in
glucose (Fig. 2A, lane 2) or in the extracts from yeast carrying the
vector (Fig. 2A, lane 3). We also checked the expression of five
missense variants: the three BRCT mutants p.A1789 T, p.I1766S,
and p.A1708E; the neutral p.P1010S; and the p.Y179C. The
expression of these proteins assessed by Western blot indicated
different levels of expression (Fig. 2A, lanes 4–8), suggesting that
the stability of the proteins may be affected by the mutations.
However, in another yeast strain this difference has not been seen,
indicating that the different protein level might be dependent on
the genetic background of the strain used [Bennett et al., 2008].
When the same amount of cells from the same culture were plated
onto galactose, the expression of BRCA1wt led to formation of
colonies much smaller than those formed by the strain carrying
the empty vector, confirming that BRCA1wt inhibited yeast
growth (Fig. 2B) [Humphrey et al., 1997; Coyne et al., 2004]. We
quantified this effect by counting the number of cells per colony
by picking up three colonies per plate and counting the cells as
previously reported [Coyne et al., 2004]. The colonies from the
BRCA1-expressing strain contained an average of 7,000 cells per
colony; on the other hand, colonies carrying the empty vector
contained an average of 459,000 cells per colony (Fig. 2C). The
missense variants p.C61G, p.N132K, p.Y179C, p.F486L, p.N550H,
p.P1010S, p.S1164I, and p.S1512I did not complement the growth
suppression phenotype, in fact the average number of cells per
colony ranged from 4,000 to 22,000 (Fig. 2C), but they could not
be classified as neutral because they map outside the BRCT
domains. The three BRCT mutants p.A1708E, p.I1766S, and
p.A1789 T fully inhibited the growth suppression, as the number
of cells per colony ranged from 402,000 to 457,500. The expression
of the p.M1775R variants that gave colonies containing about
180,500 cells per colony only partially complemented the SCP, as
reported by others (Fig. 2C) [Coyne et al., 2004; Humphrey et al.,
1997].
The Expression of Known Cancer-Related Missense
BRCA1 Variants But Not the BRCA1 Wild-Type Increased
Recombination in Yeast
The SCP assay can evaluate missense variants that are located
only within the BRCT domains of the BRCA1 protein [Billack and
Figure 1. Location of variants in BRCA1. Location of variants and negative (black triangle) and positive (open triangle) controls. SQ, serine
and threonine cluster domain; NLS, nuclear localization signal; BRCT, BRCA1 C-terminus domain; RING, RING FINGER domain. [Color figure can
be viewed in the online issue, which is available at www.interscience.wiley.com.]
Table 2. Histopathological Features of Tumors
Sample Variants Tumor Age at diagnosis Histopathology type Gradea Lymph node metastasis ER/PR
PI432 N132K Breast 47 DCI 3 – 1/1
PI340 Y179C/F486L/N550H Breast 48 DCI 3 – 1/1
PI403 Y179C/F486L/N550H Breast 42 DCI n.a. n.a. n.a.
PI98 S1512I Breast 39 DCI 3 – –/–
PI226 S1512I Breast 39 n.a. n.a. n.a. n.a.
PI222 I1766S Ovary 52 n.a. n.a. n.a. n.a.
PI335 P1010S Breast 29 DCI 3 – n.a.
PI258 A1789T Breast 32 DCI 3 – n.a.
aAccording to the Bloom-Richardson grading system for breast cancer (www.ccrcal.org/Vol_1/BloomRichardsonGradeForBreastCancer_CA.htm).
ER, estrogen receptor; PR, progesterone receptor; DCI, ductal carcinoma infiltrating; n.a., data not available; –, absence; 1, presence.
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Monteiro, 2004; Coyne et al., 2004; Humphrey et al., 1997].
Therefore, novel assays to investigate the pathogenic impact of
BRCA1 missense mutations located throughout all of the BRCA1
domains are needed. As the biological functions of BRCA1 appear
to be related to DNA repair and recombination, we tested the
effect of the expression of the wild-type and 12 missense variants
of the BRCA1 protein on yeast HR [Narod and Foulkes, 2004;
Scully et al., 2004; Zhang and Powell, 2005]. For a more complete
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evaluation we used the diploid yeast strain RS112 that contains
two distinct HR systems and, therefore, allows the simultaneous
measurement of intrachromosomal and interchromosomal re-
combination events at the HIS3 and ADE2 loci, respectively (Fig.
3A and D) [Schiestl, 1989; Schiestl, et al., 1989]. The mechanisms
by which HR occurs in this strain have been extensively studied
and we previously reported that DNA double strand breaks
formed during DNA replication are able to stimulate HR [Galli
and Schiestl, 1995, 1998, 1999; Schiestl et al., 1988]. Although this
yeast strain is widely used to study HR, there are few data on
induced recombination in galactose media. Recently, we used this
strain to screen a human cDNA library and we found that many
human cDNAs increase yeast HR by two- to six-fold in galactose
[Collavoli et al., 2008]. Here, we further characterized the HR
induction by exposing the cells to different MMS doses in
galactose or glucose SC–URA–LEU medium. Each MMS dose
induced a significant increase of intra- and interchromosomal
recombination as compared to the control. Particularly, at the
lowest MMS dose the HR was stimulated at both loci by two- to
four-fold in glucose and in galactose. The increase of HR is not
affected by the medium because both intra- and interchromoso-
mal recombination were induced to the same extent in glucose
and in galactose (Fig. 3B and D).
To determine whether BRCA1 expression affects HR, yeast cells
containing the vector with the BRCA1wt or the missense variants
under the galactose-inducible promoter were pregrown in glucose
medium. As reported in Materials and Methods, 1  107 cells
were inoculated in 5ml of galactose medium and, for comparison,
in glucose medium. Cultures were incubated at 301C for 24 hr.
Thereafter, cells were counted and plated in complete and selective
media to score for vital cells and recombinants, and incubated at
301C until colonies formed. The expression of full-length BRCA1
did not affect either HIS3 or ADE2 recombination (Fig. 3A and
B). The expression of the three variants, p.C61G (located in the
RING FINGER domain) and p.N132K and p.Y179C (located
downstream from the RING FINGER domain) induced a
significant increase of HIS3 and ADE2 recombination (Fig. 4A
and B). The expression of missense variants carrying mutation
within the DNA binding and BRCT domain gave quite different
results. The expression of the p.F486L, p.N550H, and p.P1010S
mutants did not increase recombination, while the expression of
the p.S1164I variant showed a significant increase of both intra-
and interchromosomal recombination (Fig. 3A and B). The
p.S1512I variant did not have any influence on yeast recombina-
tion, nor did the BRCT variant p.A1789 T. The expression of the
known cancer-related missense variant p.A1708E induced a
significant increase of HIS3 recombination but not of ADE2
recombination. However, the other known deleterious variant
p.M1775R significantly increased both recombination events
(Fig. 4A and B) [Mirkovic et al., 2004; Phelan et al., 2005].
Moreover, the expression of the I1766S variant showed a
significant increase of intra- and interchromosomal recombina-
tion (Fig. 4A and B). We also constructed two new BRCA1
mutants that expressed two deleted proteins: the p.R1443X and
the p.E143X. The p.R1443X deletion mutant was constructed by
the insertion of a stop codon at nucleotide 4446 in exon 13
encoding a protein lacking the BRCT domains (Fig. 1), with a
putative molecular weight of 170 kDa. The p.E143X deletion
mutant was constructed by the insertion of a stop codon at
nucleotide 546 in exon 7. The molecular weight of this truncated
protein is expected to be 17 kDa. As shown in Figure 2A, the
p.R1443X indeed is smaller than the BRCA1wt (Fig. 2A, lanes 9
and 10). When the total protein extract from yeast cells producing
the p.E143X was analyzed by western blot, no band was detectable
at high molecular weight; this demonstrated that the BRCA1wt is
not produced. On the other hand, the early truncated protein
(17 kDa) is not recognized by the antibody used (see Materials and
Methods). The expression of these BRCA1-truncated proteins did
not affect HR in yeast (Fig. 4A and B).
Discussion
Several assays have been proposed to distinguish between
cancer-related mutations and neutral polymorphisms of the
tumor suppressor gene BRCA1 [Mirkovic et al., 2004; Phelan
et al., 2002]. Prediction programs, such as SIFT and PolyPhen, are
very useful as a starting point, but often can produce
misclassification of the variants and need to be supported by
functional assays [Easton et al., 2007; Rajasekaran et al., 2007].
Transcriptional activation assays using a heterologous DNA
binding domain have been recognized as very helpful systems to
correlate the BRCA1 mutations to cancer [Monteiro and
Humphrey, 1998; Vallon-Christersson et al., 2001; Monteiro
et al., 1997]. In the present study, we chose seven missense
variants, identified among 267 breast and/or ovarian cancer
families; two nonpathogenic variants; and three cancer-related
missense variants. As novel functional assays are necessary to
classify BRCA1 missense variants as pathogenetic, we proposed to
use the yeast S. cerevisiae as genetic tool. This organism is very easy
to manipulate, simple to cultivate, and provides a large collection
of viable mutants that could be very helpful to identify new
genetic factors involved in the BRCA1 pathway [Westmoreland
et al., 2003]. The expression of full-length BRCA1, achieved by
using a galactose-inducible promoter, has been previously
reported to inhibit yeast cell growth in a haploid yeast strain
[Humphrey et al., 1997]. Here, we demonstrated that the GAL1
promoter-driven expression of full-length BRCA1 is also able to
inhibit cell growth in a diploid strain. As previously reported, only
Figure 2. Expression and effect of BRCA1 missense variant on colony size in yeast. The strain RS112 of S. cerevisiae was transformed with
plasmids carrying BRCA1wt or the selected missense variants. Single URA31 transformants were grown in –URA glucose for 24 hr at 301C and
then plated in –URA galactose. A: Western blot analysis of yeast cells expressing BRCA1wt and five missense variants; 30 &mgrg of total
proteins were loaded on each lane: lane 1, extract from RS112 expressing BRCA1wt (galactose); lane 2 and 3, extracts from noninduced RS112
(glucose) and RS112 carrying the empty vector. In lane 4 to 8, extracts from RS112 expressing the variants were loaded as follows: p.A1789 T,
p.I1766S, p.A1708E, p.P1010S, and p.Y179C. In lanes 9 and 10, extracts from yeast expressing the truncated p.R1443X protein and BRCA1wt were
loaded; in lane 11, extracts from yeast expressing the truncated p.E143X were loaded. The level of the 3-PGK was determined as loading control.
B: The expression of BRCA1wt or the missense variants affect the colony size in the RS112 strain. Here, 200–250 cells were plated in SC–URA
galactose and incubated for 4–5 days. The expression of BRCA1wt and p.S1512I gave smaller colonies than those derived from the expression of
the p.M1775R variants or from the RS112 containing the empty vector. C: The effects on colony size were quantified by counting the number of
cells per colony. Then, single colonies each plates were resuspended in 1ml water and the number of cells was counted by a hemocytometer.
Three colonies on each plate were checked for cell number. Results are reported as mean of four independent experiments7standard
deviation. [Color figure can be viewed in the online issue, which is available at www.interscience.wiley.com.]
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the BRCA1 variants carrying mutations in the BRCT domain are
capable of suppressing the growth-inhibition phenotype [Coyne
et al., 2004]. The expression of BRCT missense variants also
inhibited the growth suppression in the RS112 yeast strain,
confirming that the SCP assay could help to classify some BRCA1
missense variants as deleterious. Western blot analysis showed that
the level of the p.A1708E and p.I1766S, which suppressed the
growth inhibition phenotype, was higher than in the wild-type
and the other variants. On the other hand, the level of the variant
p.A1789 T is lower than the level of the other two BRCT variants,
indicating that the growth suppression phenotype is not due to
changes in the expression and/or stability of the BRCA1 variants.
As the SCP assay is BRCT domain–specific, we set up a novel
test named ‘‘yeast HR–based assay,’’ which could help to
distinguish the deleterious variants from the neutral polymorph-
isms. The assay measures the properties of BRCA1 variants to
affect spontaneous HR in the model organism S. cerevisiae. We
showed that the expression of the cancer-related mutations
p.C61G, p.A1708E, and p.M1775R significantly affected intra-
chromosomal and/or interchromosomal recombination in yeast,
while the neutral p.F486L and p.P1010S did not. Moreover, the
BRCA1wt did not affect yeast HR, suggesting that missense
variants that do not alter HR frequency should be considered as
potentially neutral. These results strongly suggest that the yeast S.
cerevisiae could be a useful genetic tool to classify BRCA1missense
variants as deleterious. Particularly, our results indicated that the
variants p.N132K, p.Y179C, p.S1164I, and p.I1766S should be
assessed as potentially deleterious, and the p.N550H and p.S1512I
variant as neutral. The p.A1789 T variant might also be
deleterious, although it did not affect HR as it showed a clear
effect on cell growth inhibition and clinical data showed
cosegregation with disease in the family and wild-type allele
inactivation in the tumor sample. The HR results are not
dependent on the expression level of the proteins because the
five BRCA1 variants that are expressed at different levels have
different effects on HR.
Figure 3. HR is induced by MMS in glucose and in galactose. The RS112 strain of S. cerevisiae contains two HR systems. A: The
intrachromosomal recombination event occurs between the two duplicated and differentially deleted his3 alleles, leading to the HIS3 reversion
and the loss of LEU2 [Schiestl et al., 1988]. B: The inducibility of intrachromosomal recombination was assayed in glucose and galactose media
after exposing yeast cells to different MMS doses. The frequency of intrachromosomal recombination is expressed as the number of HIS3
colonies/10,000 cells. Data are reported as mean of four independent experiments7standard deviation. Results were statistically analyzed using
the Student’s t-test. The P value waso0.001 at any MMS dose compared to the control. C: The RS112 strain is also heteroallelic for ade2-40 and
ade2-101 so that interchromosomal recombination events between homologs leading to ADE2 can be measured [Schiestl et al., 1989]. D: The
inducibility of interchromosomal recombination was determined in glucose and in galactose after exposing yeast cells to different MMS doses.
The frequency is expressed as the number of ADE2 colonies/100,000 cells. Data are reported as the mean of four independent
experiments7standard deviation. Results were statistically analyzed using the Student’s t-test. The P value was o0.001 at any MMS dose
compared to the control. Roughly, by comparing results from glucose vs. galactose, intra- and interchromosomal recombination were increased
to the same extent at both loci. [Color figure can be viewed in the online issue, which is available at www.interscience.wiley.com.]
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In general, this novel yeast recombination assay has provided
data that are in agreement with the predictive analysis carried out
by the computer programs (see Table 1). In fact, any predicted
deleterious mutation increased recombination, at least at one
locus (see Fig. 4). Although this novel functional assay is not
directly applicable in clinical practice because it requires
expressing the missense variant in yeast, it could be a very useful
aid in the evaluation of the pathological significance of BRCA1
missense variants. However, results from this assay have to be
compared and evaluated with all data obtained from other assays
to give a more complete characterization of the missense variants.
Importantly, our assay allows the characterization of mutations
located within a specific domain. Indeed, while all four BRCT
mutants were positive in the SCP assay, 3 out of 4 BRCTmutants
affected HR.
DNA damage such as double strand breaks induces HR in
mitotically growing cells of S. cerevisiae in order to repair the DNA
[Galli and Schiestl, 1995, 1998; Kupiec, 2000]. Conversely in
mammalian cells, DNA double strand breaks are primarily
repaired by nonhomologous end joining. In addition, HR
has been shown to provide a very faithful and efficient
DNA repair pathway mainly in mammalian replicating
cells where it is critical to maintain genome integrity [West,
2003]. The main goal of this study is to develop a new assay to
characterize BRCA1 missense variants and not to deeply
investigate the role of BRCA1 in HR. However, we could
hypothesize that those BRCA1 variants affecting recombination
could have some impact on yeast DNA repair or interact with
proteins that lead to an elevated level of endogenous DNA
damage. Recently, we reported that BRCA1 interaction with the
carboxy-terminal domain of RNA polymerase II is mediated by
the BRCT domain of BRCA1 [Bennett et al., 2008]. To address
whether the BRCT domain was important for HR, we measured
the HR in the strain expressing the BRCT deleted p.R1443X
variant. As this protein did not affect recombination, we conclude
that this domain is involved in HR. As expected, the early-
truncated p.R143X did not affect HR again indicating that
protein-protein interactions are important.
Figure 4. Effect of BRCA1 missense variant expression on yeast HR. Single colonies of the RS112 strain containing the plasmid expressing
the BRCA1wt or missense variants were first pregrown in glucose. Then, 107 cells were inoculated in glucose and galactose medium for 24 hr at
301C. As described in Materials and Methods, cells were counted and plated to score for cell surviving fraction, the frequency of HIS3
intrachromosomal recombination, and ADE2 interchromosomal recombination. A: Effect of BRCA1 protein expression on HIS3 intrachromosomal
recombination. B: Effect of BRCA1 protein expression on ADE2 interchromosomal recombination. Data are reported as mean of six to nine
independent experiments7standard deviation. Results were statistically analyzed using the Student’s t-test. Po0.05, Po0.01, Po0.001.
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Some yeast mutants affecting DNA replication have a
hyperrecombination phenotype, indicating that HR is also
stimulated when the DNA replication is impaired [Galli et al.,
2003]. Although there is no direct evidence that BRCA1 is directly
involved in DNA replication, it interacts with several proteins that
function in cell cycle checkpoint activation and the genome
surveillance complex [Wang et al., 2000; Durant and Nickoloff,
2005]. Many BRCA1 interacting proteins have a yeast counterpart;
therefore, the expression of such variants could affect the activity
of these proteins leading to an increase of HR. It seems somehow
contradictory that some BRCA1 variants negative in the SCP
assay and, therefore, growth suppressors, were able to increase HR
as much as the BRCA1wt. This is probably due to the profound
difference between the two assays. In the SCP assay, yeast cells are
plated onto galactose and incubated for several days (4–6 days).
During that time, the BRCA1wt protein can accumulate and,
consequently, inhibit the ‘‘colony’’ growth. We basically measured
the colony growing efficiency of a single cell that has been ‘‘forced’’
to form a colony. In the recombination assay, yeast cells were
grown for 24 hr in galactose or glucose, washed, and then plated in
glucose media to score for recombinants and survivors. Therefore,
this assay measures the HR events occurring during the 24-hr
induction in liquid medium. To determine whether the growth
suppressor variants inhibited cell replication during the 24 hr in
galactose, the colony-forming efficiency of the BRCA1wt-expres-
sing strain was measured after 24 hr in galactose by plating 200
cells per plate in glucose medium. The results showed that the
colony-forming efficiency was as high as 80% and, under 24-hr
galactose induction, the culture underwent one replication cycle.
This indicates that DNA replication has occurred and could be
related to HR.
As mentioned before, BRCA1 is involved in many aspects of
DNA damage response and affects DNA double strand break
repair, cell cycle checkpoint, and HR; therefore, this novel
functional assay could be also exploited to investigate the
biological activity of BRCA1 and the mechanisms underlying
BRCA1 tumorigenesis [Deng, 2006; Narod and Foulkes, 2004;
Durant and Nickoloff, 2005].
The HR assay clearly has potential predictive value and can be
added to the other previously used modalities to help under-
standing the pathogenic role of specific BRCA1 variants. However,
the characteristics of the assay are not well defined and, like SIFT
and PolyPhen, the yeast-based HR assay is not yet applicable in the
clinical setting with a high level of confidence.
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